The Interleukin‐1 Receptor–Associated Kinase 4 Inhibitor PF‐06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial

OBJECTIVE: To investigate the role of PF‐06650833, a highly potent and selective small‐molecule inhibitor of interleukin‐1–associated kinase 4 (IRAK4), in autoimmune pathophysiology in vitro, in vivo, and in the clinical setting. METHODS: Rheumatoid arthritis (RA) inflammatory pathophysiology was mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Winkler, Aaron, Sun, Weiyong, De, Saurav, Jiao, Aiping, Sharif, M. Nusrat, Symanowicz, Peter T., Athale, Shruti, Shin, Julia H., Wang, Ju, Jacobson, Bruce A., Ramsey, Simeon J., Dower, Ken, Andreyeva, Tatyana, Liu, Heng, Hegen, Martin, Homer, Bruce L., Brodfuehrer, Joanne, Tilley, Mera, Gilbert, Steven A., Danto, Spencer I., Beebe, Jean J., Barnes, Betsy J., Pascual, Virginia, Lin, Lih‐Ling, Kilty, Iain, Fleming, Margaret, Rao, Vikram R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671219/
https://www.ncbi.nlm.nih.gov/pubmed/34423919
http://dx.doi.org/10.1002/art.41953

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671219/
https://www.ncbi.nlm.nih.gov/pubmed/34423919
http://dx.doi.org/10.1002/art.41953

Ejemplares similares